These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1565 related articles for article (PubMed ID: 28126323)

  • 1. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
    Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
    Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.
    Cholewa BD; Ndiaye MA; Huang W; Liu X; Ahmad N
    Cancer Lett; 2017 Jan; 385():179-187. PubMed ID: 27793694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential Cellular Effects of Plk1 Inhibitors Targeting the ATP-binding Domain or Polo-box Domain.
    Shin SB; Woo SU; Yim H
    J Cell Physiol; 2015 Dec; 230(12):3057-67. PubMed ID: 25975351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
    Lin C; Lu W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Cao W; Wang L; Wang X; Ji T
    Cancer Lett; 2016 Jul; 377(1):1-10. PubMed ID: 27090738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCl-1 and XIAP Antiapoptotic Proteins.
    Tanaka N; Patel AA; Wang J; Frederick MJ; Kalu NN; Zhao M; Fitzgerald AL; Xie TX; Silver NL; Caulin C; Zhou G; Skinner HD; Johnson FM; Myers JN; Osman AA
    Clin Cancer Res; 2015 Nov; 21(21):4831-44. PubMed ID: 26124202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer.
    Ferrarotto R; Goonatilake R; Yoo SY; Tong P; Giri U; Peng S; Minna J; Girard L; Wang Y; Wang L; Li L; Diao L; Peng DH; Gibbons DL; Glisson BS; Heymach JV; Wang J; Byers LA; Johnson FM
    Clin Cancer Res; 2016 Apr; 22(7):1674-1686. PubMed ID: 26597303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PLK1 is a critical determinant of tumor cell sensitivity to CPT11 and its inhibition enhances the drug antitumor efficacy in squamous cell carcinoma models sensitive and resistant to camptothecins.
    Zuco V; De Cesare M; Zaffaroni N; Lanzi C; Cassinelli G
    Oncotarget; 2015 Apr; 6(11):8736-49. PubMed ID: 25826089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma models.
    Pajtler KW; Sadowski N; Ackermann S; Althoff K; Schönbeck K; Batzke K; Schäfers S; Odersky A; Heukamp L; Astrahantseff K; Künkele A; Deubzer HE; Schramm A; Sprüssel A; Thor T; Lindner S; Eggert A; Fischer M; Schulte JH
    Oncotarget; 2017 Jan; 8(4):6730-6741. PubMed ID: 28036269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reciprocal activation between PLK1 and Stat3 contributes to survival and proliferation of esophageal cancer cells.
    Zhang Y; Du XL; Wang CJ; Lin DC; Ruan X; Feng YB; Huo YQ; Peng H; Cui JL; Zhang TT; Wang YQ; Zhang H; Zhan QM; Wang MR
    Gastroenterology; 2012 Mar; 142(3):521-530.e3. PubMed ID: 22108192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wee-1 kinase inhibition overcomes cisplatin resistance associated with high-risk TP53 mutations in head and neck cancer through mitotic arrest followed by senescence.
    Osman AA; Monroe MM; Ortega Alves MV; Patel AA; Katsonis P; Fitzgerald AL; Neskey DM; Frederick MJ; Woo SH; Caulin C; Hsu TK; McDonald TO; Kimmel M; Meyn RE; Lichtarge O; Myers JN
    Mol Cancer Ther; 2015 Feb; 14(2):608-19. PubMed ID: 25504633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Polo-like kinase 1 inhibitor onvansertib represents a relevant treatment for head and neck squamous cell carcinoma resistant to cisplatin and radiotherapy.
    Hagege A; Ambrosetti D; Boyer J; Bozec A; Doyen J; Chamorey E; He X; Bourget I; Rousset J; Saada E; Rastoin O; Parola J; Luciano F; Cao Y; Pagès G; Dufies M
    Theranostics; 2021; 11(19):9571-9586. PubMed ID: 34646387
    [No Abstract]   [Full Text] [Related]  

  • 12. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
    Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM
    Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ER maleate is a novel anticancer agent in oral cancer: implications for cancer therapy.
    Fu G; Somasundaram RT; Jessa F; Srivastava G; MacMillan C; Witterick I; Walfish PG; Ralhan R
    Oncotarget; 2016 Mar; 7(13):17162-81. PubMed ID: 26934445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma.
    Chilà R; Basana A; Lupi M; Guffanti F; Gaudio E; Rinaldi A; Cascione L; Restelli V; Tarantelli C; Bertoni F; Damia G; Carrassa L
    Oncotarget; 2015 Feb; 6(5):3394-408. PubMed ID: 25428911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting polo-like kinase 1 enhances radiation efficacy for head-and-neck squamous cell carcinoma.
    Gerster K; Shi W; Ng B; Yue S; Ito E; Waldron J; Gilbert R; Liu FF
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):253-60. PubMed ID: 20394857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
    Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
    J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The PLK1 inhibitor GSK461364A is effective in poorly differentiated and anaplastic thyroid carcinoma cells, independent of the nature of their driver mutations.
    Russo MA; Kang KS; Di Cristofano A
    Thyroid; 2013 Oct; 23(10):1284-93. PubMed ID: 23509868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eribulin synergizes with Polo-like kinase 1 inhibitors to induce apoptosis in rhabdomyosarcoma.
    Stehle A; Hugle M; Fulda S
    Cancer Lett; 2015 Aug; 365(1):37-46. PubMed ID: 25917079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53.
    Gadhikar MA; Sciuto MR; Alves MV; Pickering CR; Osman AA; Neskey DM; Zhao M; Fitzgerald AL; Myers JN; Frederick MJ
    Mol Cancer Ther; 2013 Sep; 12(9):1860-73. PubMed ID: 23839309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acetyl-macrocalin B suppresses tumor growth in esophageal squamous cell carcinoma and exhibits synergistic anti-cancer effects with the Chk1/2 inhibitor AZD7762.
    Wang JN; Che Y; Yuan ZY; Lu ZL; Li Y; Zhang ZR; Li N; Li RD; Wan J; Sun HD; Sun N; Puno PT; He J
    Toxicol Appl Pharmacol; 2019 Feb; 365():71-83. PubMed ID: 30633885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 79.